Physician Assistant Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Holladay

Physician Assistant Strasburg, VA Physician Assistant

NPI 1376044750 CMS profile 5013075

33699 Old Valley Pike, Strasburg, VA 22657

Open in the dashboard

General payments

$1,804

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Holladay of Strasburg, VA is reported in the CMS Open Payments database as having received $1,804 across 108 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $443 24
2024 General $462 30
2023 General $452 27
2022 General $93 6
2021 General $343 20
2019 General $11 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Holladay
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Elizabeth Holladay were reported at $443. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Elizabeth Holladay Physician Assistant median Middle half National median
2019 $11 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $343 $132 $37–$438 $132
2022 $93 $155 $48–$522 $149
2023 $452 $167 $52–$557 $160
2024 $462 $178 $55–$600 $164
2025 $443 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $437 29 payments
  2. Novo Nordisk Inc $379 23 payments
  3. Lilly USA, LLC $270 15 payments
  4. AstraZeneca Pharmaceuticals LP $169 11 payments
  5. Amgen Inc. $145 9 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $141 6 payments
  7. Verona Pharma, Inc. $81 4 payments
  8. Viatris Specialty LLC $44 2 payments
  9. GlaxoSmithKline, LLC. $34 2 payments
  10. Dynavax Technologies Corporation $32 2 payments
  11. Other $71 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,791 107 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $349 21 payments
  2. RYBELSUS $314 19 payments
  3. PREVNAR 20 $266 19 payments
  4. COMIRNATY $266 19 payments
  5. MOUNJARO $213 11 payments
  6. ABRYSVO $198 15 payments
  7. PAXLOVID $116 7 payments
  8. NURTEC ODT $112 7 payments
  9. BREZTRI $106 7 payments
  10. PREMARIN $84 4 payments
  11. Other $1,181 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 91 drugs

Part D claims

4,153

Median for Physician Assistant: 241

Drug cost

$321,910

Median for Physician Assistant: $4,110

Branded share of claims

19.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 45 $49,997
Jardiance Empagliflozin Brand 47 $45,078
Eliquis Apixaban Brand 42 $34,683
Ozempic Semaglutide Brand 16 $28,136
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 42 $27,975
Tresiba Flextouch U-200 Insulin Degludec Brand 21 $19,463
Mounjaro Tirzepatide Brand 18 $19,242
Xarelto Rivaroxaban Brand 19 $16,857
Rybelsus Semaglutide Brand 15 $13,957
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $12,328

The 10 drugs with the highest cost, of 91 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $72
$72 42 —
MOUNJARO
  • Lilly USA, LLC $55
$55 18 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $48
$48 — —
RYBELSUS
  • Novo Nordisk Inc $33
$33 15 —
Ozempic
  • Novo Nordisk Inc $33
$33 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record